Axiogenesis AG is committed to producing and publishing high-quality science to advance the field of stem cell research and drug development.  See below for selected peer-reviewed publications.  

Have you published using Axiogenesis technology or products?  Let us know so we may reference your work.

2014

Action Potential Characterization of Human iPSC-derived Cardiomyocytes using Automated Patch-Clamp Technology.  Scheel O, Frech S, Amuzescu B, Eisfeld J, Lin K, Knott T; Assay and Drug Development Technologies (abstract)
L-Type Ca++ Channel Responses to Bay K 8644 in Stem Cell-Derived Cardiomyocytes Are Unusually Dependent on Holding Potential and Charge Carrier.  Ji J, Kang J, Rampe D; Assay and Drug Development Technologies, Vol. 12, No. 6, July/August 2014. (Full Text PDF)
Micromolded gelatin hydrogels for extended culture of engineered cardiac tissues.  McCain ML, Agarwal A, Nesmith HW, Nesmith AP, Parker KK; Biomaterials, Vol. 35, Issue 21, July 2014, 5462-5471. (abstract)
Quality Metrics for Stem Cell-Derived Cardiac Myocytes.  Sheehy S, Pasqualini F, Grosberg A, Park SJ, Aratyn-Schaus Y, Parker KK; Stem Cell Reports, Vol. 2, 282-294, 11 March 2014.  (Full Text PDF)
2013

Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: Effects of reference compounds.Himmel HM; J PharmTox, 2013 Jul/Aug; 68: 97-111.
Minimized cell usage for stem cell-derived and primary cells on an automated patch clamp system.  Becker N, Stoelzle S, Goepel S, Guinot D, Mumm P Haarmann C, Malan D, Bohlen H, Kossolov E, Kettenhofen R, George M, Fertig N, Brueggemann A; J PharmTox, 2013 Jul/Aug; 68: 82-87.
2012

Differentiation and selection of hepatocyte precursors in suspension spheroid culture of transgenic murine embryopnic stem cells. Gabriel E, Schievenbusch S, Kolossov E, Hengstler JG, Rotsheyn T, Bohlen H, Nierhoff D, Hescheler J, Drobinskaya I, PLoS One. 2012;7(9):e44912. doi:10. 1371/journal.pone.0044912. Epub 2012 Sep 24.  (open source)
Dynamic monitoring of beating periodicity of stem cell derived cardiomyocytes as a predictive tool for preclinical safety assesment. Abassi YA, Xi B, Li N, Ouyang W, Seiler A, Matzele M, Kettenhofen R, Bohlen H, Ehlöich A, Kolossov E, Wang X, Xu X. Br J Pharmacol. 2012 Mar;165(5):1424-41.
2011

State of the Art Automated Patch Clamp Devices: Heat Activation, Action Potentials, and High Throughput in Ion Channel Screening. Stölzle S, Obergrussberger A, Brüggemann A, Haarmann C, George M, Kettenhofen R, Fertig N. Front Pharmacol. 2011;2:76. Epub 2011 Nov 24.
MicroRNA profiling during cardiomyocyte specific differentiation of murine embryonic stem cells based on two different miRNAarray platforms. Gan L, Schwengberg S, Deneke B.PLoS One. 2011;6(10):e25809. Epub 2011 Oct 3. (open source)
Automated patch clampon mESC-derived cardiomyocytes for cardiotoxicity prediction.  Stölzle S, Haythornwaite A, Kettenhofen R, Kolossov E, Hohlen H, George M, Brüggemann A, Fertig N. J Biomol Screen. 2011 Sep;16(8):910-6. Epub 2011 Jul 20.
Cardiac Toxicity.Kettenhofen R, Schwengberg S, in: ADMET for Med icinal Chemists, Eds.: Tsaioun K, Kates SA.
2010

Embryonic stem cells as a tool for drug screening and toxicity testing. Schwengberg S, in: Stem Cell Engineering, Eds.: Artmann GM, Minger S, Hescheler J. (Publication 1st ed April 2010, Springer;link.)
Chemically induced cardiomyogenesis of mouse embryonic stem cells. Berkessel A, Seelig B, Schwengberg S, Hescheler J, Sachinidis A. Chembiochem. 2010 Jan 25;11(2):208-17; link.
2009

A review of the implementation of the embryonic stem cell test (EST). The report and recommendations of an ECVAM/ReProTect Workshop. Marx-Stoelting P, Adriaens E, Ahr HJ, Bremer S, Garthoff B, Gelbke HP, Piersma A, Pellizzer C, Reuter U, Rogiers V, Schenk B, Schwengberg S, Seiler A, Spielmann H, Steemans M, Stedman DB, Vanparys P, Vericat JA, Verwei M, van der Water F, Weimer M, Schwarz M. Altern Lab Anim. 2009 Jul;37(3):313-28; link.
Response to “The microEST in vitro test for embryotoxicity – a case of mistaken identity?” by Robert Combes. Schwengberg S, Bohlen H, Fronhoff B. Toxicol In Vitro. 2009 Mar;23(2):362-3. Epub 2008 Dec 10; link.
  2008

 

Pre-clinical assessment of cardiac toxicity. Kettenhofen R, Bohlen H; Drug Discovery Today 2008 Aug:13(15-16):702-7. Epub 2008 Jul 24; link.
Scalable selection of Hepatocyte- and Hepatocyte precursor-like cells from transgenic murine ES cells. Dobrinskaya I, Linn T, Saric T, Bretzel RG, Bohlen H, Hescheler J, Kolossov E; Stem Cells 2008 Sep;26(9):2245-56. Epub 2008 Jun 12; link.
Genetic modification of cells for transplantation. Lai Y, Dobrinskava I, Kolossov E, Chen C, Linn T; Adv Drug Deliv Rev. 2008 Jan 14:60(2):146-59. Epub 2007 Oct 18. Review; link.
2007

Potential risks of bone marrow cell transplantation into infarcted hearts. Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, Nygren JM, Fries JW, Tiemann K, Bohlen H, Hescheler J, Welz A, Bloch W, Jacobsen SE, Fleischmann BK. Blood. 2007 Aug 15;110(4):1362-9. Epub 2007 May 4; link.
2006

Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium. Kolossov E, Bostani T, Roell W, Breitbach M, Pillekamp F, Nygren JM, Sasse P, Rubenchik O, Fries JW, Wenzel D, Geisen C, Xia Y, Lu Z, Duan Y, Kettenhofen R, Jovinge S, Bloch W, Bohlen H, Welz A, Hescheler J, Jacobsen SE, Fleischmann BK. J Exp Med. 2006 Oct 2;203(10):2315-27 . Epub 2006 Sep 5; link.
Antibody repertoires generated by VH replacement and direct VH to JH joining.Koralov SB, Novobrantseva TI, Konigsmann J, Ehlich A, Rajewsky K. Immunity. 2006 Jul;25(1):43-53; link .
Identification of Small Signalling Molecules Promoting Cardiac-Specific Differentiation of Mouse Embryonic Stem Cells Sachinidis A, Schwengberg S, Hippler-Altenburg R, Mariappan D, Kamisetti N, Seelig B, Berkessel A, Hescheler J. Cell Physiol Biochem 2006;18:303-314; link.
2005

Identification and characterization of embryonic stem cell-derived pacemaker and atrial cardiomyocytes. Kolossov E, Lu Z, Drobinskaya I, Gassanov N, Duan Y, Sauer H, Manzke O, Bloch W, Bohlen H, Hescheler J, Fleischmann BK. FASEB J. 2005 Apr;19(6):577-9. Epub 2005 Jan 19; link.
In vitro embryotoxicity assessment with dental restorative materials. Schwengberg S, Bohlen H, Kleinsasser N, Kehe K, Seiss M, Walther UI, Hickel R, Reichl FX. J Dent. 2005 Jan;33(1):49-55; link.
Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Weihrauch MR, Ansen S, Jurkiewicz E, Geisen C, Xia Z, Anderson KS, Gracien E, Schmidt M, Wittig B, Diehl V, Wolf J, Bohlen H, Nadler LM. Clin Cancer Res. 2005 Aug 15;11(16):5993-6001;link.
Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin’s disease: potential for a prognostic factor. Weihrauch MR, Manzke O, Beyer M, Haverkamp H, Diehl V, Bohlen H, Wolf J, Schultze JL. Cancer Res. 2005 Jul 1;65(13):5516-9; link.
2004

Differential subunit composition of the G protein-activated inward-rectifier potassium channel during cardiac development. Fleischmann BK, Duan Y, Fan Y, Schoneberg T, Ehlich A, Lenka N, Viatchenko-Karpinski S, Pott L, Hescheler J, Fakler B. J Clin Invest. 2004 Oct;114(7):994-1001 ; link.
Determination of electrical properties of ES cell-derived cardiomyocytes using MEAs. Hescheler J, Halbach M, Egert U, Lu ZJ, Bohlen H, Fleischmann BK, Reppel M. J Electrocardiol. 2004;37 Suppl:110-6. Review; link.
Implication of therapeutic cloning for organ transplantation. Hescheler J, Wartenberg M, Wenzel D, Roell BK, Lu Z, Xia Y, Donmez F, Ling FC, Acker H, Kolossov E, Kazemi S, Sasse P, Raible A, Bohlen H, Bloch W, Sauer H, Welz A, Fleischmann BK. Eur J Cardiothorac Surg. 2004 Dec;26 Suppl 1:S54-5; discussion S55-6. Review; link.
Activity of complex III of the mitochondrial electron transport chain is essential for early heart muscle cell differentiation. Spitkovsky D, Sasse P, Kolossov E, Bottinger C, Fleischmann BK, Hescheler J, Wiesner RJ. FASEB J. 2004 Aug;18(11):1300-2. Epub 2004 Jun 4; link.
2003

Host-dependent tumorigenesis of embryonic stem cell transplantation in experimental stroke. Erdo F, Buhrle C, Blunk J, Hoehn M, Xia Y, Fleischmann B, Focking M, Kustermann E, Kolossov E, Hescheler J, Hossmann KA, Trapp T. J Cereb Blood Flow Metab. 2003 Jul;23(7):780-5; link.
Cardiac specific differentiation of mouse embryonic stem cells. Sachinidis A, Fleischmann BK, Kolossov E, Wartenberg M, Sauer H, Hescheler J. Cardiovasc Res. 2003 May 1;58(2):278-91. Review; link.
2002

Differential role of bFGF and VEGF for vasculogenesis. Kazemi S, Wenzel D, Kolossov E, Lenka N, Raible A, Sasse P, Hescheler J, Addicks K, Fleischmann BK, Bloch W. Cell Physiol Biochem. 2002;12(2-3):55-62; link.
Cellular cardiomyoplasty in a transgenic mouse model. Roell W, Fan Y, Xia Y, Stoecker E, Sasse P, Kolossov E, Bloch W, Metzner H, Schmitz C, Addicks K, Hescheler J, Welz A, Fleischmann BK. Transplantation. 2002 Feb 15;73(3):462-5; link.
Cellular cardiomyoplasty improves survival after myocardial injury. Roell W, Lu ZJ, Bloch W, Siedner S, Tiemann K, Xia Y, Stoecker E, Fleischmann M, Bohlen H, Stehle R, Kolossov E, Brem G, Addicks K, Pfitzer G, Welz A, Hescheler J, Fleischmann BK. Circulation. 2002 May 21;105(20):2435-4; link.